Course Description

One of the major challenges facing every level of sport today is the use of performance-enhancing substances. Left unchecked, this problem has the potential to destroy the health of innumerable athletes as well as undermine the integrity, value, and purpose of sport.

This conference aims to raise understanding of the reasons behind an athlete’s decision whether or not to use performance-enhancing drugs and approaches to deter an athlete’s usage, primarily through scientific research-based solutions.

Educational Objectives

At the conclusion of this program, participants should be better able to:

◆ Understand the factors influencing an athlete’s decision whether or not to use performance-enhancing drugs
◆ Learn approaches used to deter use of performance-enhancing drugs
◆ Identify future strategies to enhance current drug testing approaches
◆ Learn how PCC funding furthers research to improve testing methods

Course Chair

Gary Green, MD
Clinical Professor, Division of Sports Medicine
David Geffen School of Medicine at UCLA
Member, PCC Scientific Advisory Board
Los Angeles, California

Andrew N. Hoofnagle, MD, PhD
Assistant Professor of Laboratory Medicine
Director of Clinical Mass Spectrometry
University of Washington
Seattle, Washington

Speakers and Curriculum Consultants

Gerhard Baumann, MD
Professor of Medicine Emeritus
Northwestern University
Evanston, Illinois

David Howman
Director General
World Anti-Doping Agency (WADA)
Montreal, Quebec, Canada

Larry D. Bowers, PhD
Chairman, PCC Scientific Advisory Board
Chief Science Officer
United States Anti-Doping Agency (USADA)
Colorado Springs, Colorado

Daniel Mullin
Senior Vice President
Security and Investigations
Major League Baseball
New York, New York

Anthony W. Butch, PhD
Director, UCLA Olympic Analytical Laboratory
Professor, Pathology & Laboratory Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Nunzianda Frascione, PhD
Department of Forensic Science and Drug Monitoring
School of Biomedical and Health Sciences
King’s College London
London, United Kingdom

Bryan S. Finkle, PhD
Member, PCC Scientific Advisory Board
Consultant Forensic Toxicologist
National Football League
Cameron, Montana

Douglas M. Glanville
Former Professional Baseball Player
ESPN Baseball Analyst
Op-Extra Columnist at The New York Times
Author, The Game From Where I Stand
Chicago, Illinois

Andrew Pipe, CM, MD
Chief, Division of Prevention and Rehabilitation
University of Ottawa Heart Institute
Professor of Medicine
University of Ottawa
Ottawa, Canada

Travis T. Tygart
Chief Executive Officer
United States Anti-Doping Agency (USADA)
Member, PCC Board of Governors
Colorado Springs, Colorado

Peter Van Eenoo, PhD
Head of DoCoLab
Post-Doctoral Scientist
Ghent University
Ghent, Belgium
The Doping Decision: Deterring Doping in Sport
Thursday, December 1, 2011
NFL Offices 345 Park Avenue, New York, New York
REGISTER NOW FOR THE 2011 PCC CONFERENCE

The Doping Decision: Deterring Doping in Sport

Thursday, December 1, 2011
NFL Offices, 345 Park Avenue, New York, New York 10134

Presented by
Partnership for Clean Competition and
The Office of Continuing Medical Education
David Geffen School of Medicine at UCLA

also supported by
Program

Thursday, December 1, 2011

Morning
9:00 Welcome and Introductory Remarks

9:10 Keynote Address: Trends and Progress in the Fight Against Doping in Sport
David Howman

Session 1: The Doping Decision

9:40 Why We Play: Values, Drugs and Sport
Thomas H. Murray, PhD

10:00 A Super Athlete’s Dilemma
Douglas M. Glanville

10:20 The Role of Influencers
Andrew Pipe, CM, MD

Q & A

11:00 Break

11:15 Deterrence Models
Larry D. Bowers, PhD

Session 2: Progress in Detection

11:30 Can Genomic Analysis Be the Answer to Autologous Blood Transfusion Detection?
Nunzianda Frascione, PhD

11:50 Preliminary Data on IRMS Reference Intervals and hCG Project
Anthony W. Butch, PhD

12:10 Metabolism of Steroids via the Chimeric Mouse with Humanized Liver
Peter Van Eenoo, PhD

Q & A

Afternoon
12:30 Lunch and Networking

Session 3: Confronting hGH

1:30 Current State-of-the Art in Growth Hormone Testing
Gerhard Baumann, MD

1:50 Measuring Proteins Using Mass Spectrometry
Andrew N. Hoofnagle, MD, PhD

Q & A

2:30 Break

Session 4: Role of Intelligence

Session 4 will consist of speakers and a panel discussion addressing the importance of continuing to gain additional intelligence in fighting doping in sport. Among other approaches, coordinating with law enforcement and understanding athlete usage patterns and behaviors can generate information to improve deterrence and detection.

3:45 Concluding Remarks

4:00 Adjourn

The PCC is an innovative research collaborative founded by the U.S. Olympic Committee, United States Anti-Doping Agency, Major League Baseball and the National Football League, whose focus is to fund non-partisan and independent scientific research that has a high likelihood of developing new methods and products that will advance the anti-doping field and ensure integrity in sport. Also participating and contributing financially to the PCC are the National Basketball Association, National Hockey League and the PGA Tour.
Tuition
$125.00 (without credit*) if registered by November 1, 2011
$150.00 (without credit*) registration after November 1, 2011
$25 additional fee for CME credit*
(fee includes registration, lunch and course materials)

Location
National Football League Offices
345 Park Avenue
New York, NY 10154

Accreditation
The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
The Food and Drug Administration has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy now mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. We at UCLA fully endorse the letter and spirit of these concepts.

Accommodations
A special rate has been arranged at the New York Marriott East Side, 525 Lexington Ave., New York, NY 10017. The NFL has reserved a limited block of rooms, requests for rooms will be filled on a first come first served basis. In the next column is the hotel link with additional information regarding the special rate requirements.

Hotel Link
Partnership for Clean Competition hotel website:
http://events.nfl.info/hotelrequest/
Partnership_for_Clean_Competition

Hotel Rates
Standard Room $299, plus tax, for night of November 30, reservation made by November 1.
Standard Room $399, plus tax, for night of December 1 and reservation made after November 1.
Questions regarding the hotel link please contact Sunday Billings in the NFL Events Department at 212-450-2185 or Sunday.Billings@NFL.com.

Enrollment
Online
Use your MasterCard, VISA, American Express, or Discover card. Go to www.cme.ucla.edu and click on “The Doping Decision: Detering Doping in Sport”

By Mail
Use a check or a MasterCard, VISA, or Discover card. Please use the attached form and include either your check or charge card information and authorizing signature. For additional applications, use a photocopy or separate sheet giving all information requested on the form.

By Phone
Call 310-794-2620.

By FAX
Send the completed enrollment form with charge card information and authorizing signature to the Office of Continuing Medical Education at 310-794-2624.

Refunds
Cancellations must be received in writing by November 15, 2011, and will be subject to a $25 processing fee. No refunds will be given after that date. If, for any reason, the course must be canceled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided. You may fax your refund request to 310-794-2624.

For additional information, contact the Office of Continuing Medical Education David Geffen School of Medicine at UCLA 10920 Wilshire Boulevard, Suite 1060 Los Angeles, CA 90024-6512, 310-794-2620 E-Mail: eayala@mednet.ucla.edu.
PCC contact: Jill Zeldin at jzeldin@cleancompetition.org or 719-866-3306
Registration

Partnership for Clean Competition 2011 Conference
The Doping Decision: Deterring Doping in Sport

Course Number: M112-15

Registration Fees:  ❑ $125.00 by November 1, 2011  or  ❑ $150.00 after November 1, 2011
❑ $25 additional fee for optional CME credit
Total (circle) $125, $150, $175

For a hotel room please use the following link:
http://events.nfl.info/hotelrequest/Partnership_for_Clean_Competition

Please print.

Last four digits of Social Security Number

Name (First, Last, Degree)  ❑ Male  ❑ Female

Title

Organization

Preferred Mailing Address

City/State/Zip

Phone    Fax

Field of Practice

E-mail Address

❑ Check enclosed, payable to The Regents of the University of California

Charge:  ❑ MasterCard  ❑ Visa  ❑ Discover  ❑ American Express

Card Number

Authorizing Signature   Expiration Date

Mail to Office of Continuing Medical Education
David Geffen School of Medicine at UCLA
PCC 2011 Conference
10920 Wilshire Blvd., Ste. 1060
Los Angeles, CA 90024-6512

Fax to 310-794-2624